antiviral news

The results mark the first late-stage success for an oral antiviral used to prevent COVID-19 after exposure.

Paxlovid’s role in treating COVID-19 is not ending — it is evolving, according to the results of two national trials published in The New England Journal of Medicine.Although the trials — one conducted in the United Kingdom (PANORAMIC) and the other in Canada (CanTreatCOVID) — determined that Paxlovid (nirmatrelvir-ritonavir, Pfizer) does not reduce the incidence of hospitalization or death among vaccinated high-risk patients with SARS-CoV-2 compared with usual care, the combination medication sped up recovery in a meaningful way, experts noted.Nirmatrelvir-ritonavir is an antiviral regimen

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, were published in the New England Journal of Medicine. A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compare

Study found nirmatrelvir–ritonavir did not reduce severe outcomes in vaccinated COVID-19 patients, though symptom recovery improved.

St. Michael’s Hospital’s Upstream Lab uncovers new evidence which could shape decisions on Paxlovid use for COVID-19

Studies suggest Paxlovid may not prevent severe COVID-19 outcomes in vaccinated individuals but could reduce recovery time and viral load.